交银国际:升三生制药(01530.HK)目标价至33港元 维持“买入”评级

智通财经
30 Jul
【交银国际:升三生制药(01530.HK)目标价至33港元 维持“买入”评级】智通财经APP获悉,交银国际发布研报称,基于更高的合作收入预测,上调三生制药(01530.HK)2025-2027年收入预测2-6%;同时考虑到高定价的创新药和高利润率的合作收入对总收入的贡献逐步提高,上调利润率预测,最终净利润预测上调6-9%,目标价升至33港元,对应25.8倍、23.9倍2025年/2026年市盈率,维持“买入”评级。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10